Augtyro was recommended as monotherapy for the treatment of adult and pediatric patients 12 years of age and older with advanced solid tumors expressing a NTRK gene fusion and (1) have received a ...
The final EC decision is expected in January 2025. “Patients in the EU with ROS1 -positive non-small cell lung cancer and NTRK -positive solid tumours face a great unmet need for new therapies that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback